Wharton’s Jelly Derived Mesenchymal Stromal Cells and Secretome in the treatment of Autism: an observational Case Report - Abstract
Autism spectrum disorder (ASD), is a set of heterogenous neurodevelopmental disorder strongly linked with genetic and environmental factors and characterized by atypical patterns of repetitive verbal and nonverbal behaviours including dysfunction in social interaction and communication skills .Though remain unclear , recent evidence has suggested that immune dysregulation as well as neuroinflammation has an a etiological role. In particular, elevation of pro-inflammatory cytokines and chemokines as well as cytokine imbalances in CSF and blood are associated with behavioural and cognitive impairment and dysfunction of immune cells. The current treatment approach consisting of behavioral therapies, pharmacological and nutritional supplementation is at best providing symptomatic relieve. Given the steady rise of ASD over the past decade, there is an urgent need to provide effective therapeutic solutions. Mesenchymal cells well recognised for its immunomodulatory capabilities has the ability to reduce the impact of inflammation and tissue damage. We present here a case of Autism in a 5 year old female who following two intravenous implantation of Wharton’s jelly derived mesenchymal stromal cells (WJMSC transplantation) and 4 intramuscular secretome demonstrated improvement in eye coordination, verbal communication, gross and fine motor skills, social skills and emotional regulation. The therapeutic effects of MSC is likely attributed to cell mediated modulation, molecular mediated neuroprotection and restoration of functional neurologic circuitry. There has been no adverse reaction reported during the one year follow-up. Hence it is reasonable to consider WJ-MSC and secretome as an adjunct therapy to conventional approaches in the management of ASD.